Stockreport

Denali Therapeutics' ALS therapy fails to meet primary endpoint in Phase II/III trial [Yahoo! Finance]

Denali Therapeutics Inc.  (DNLI) 
Last denali therapeutics inc. earnings: 8/6 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.denalitherapeutics.com
PDF The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo. The drug was investigated as part of the HEALEY ALS Platf [Read more]